ERAS
Price
$2.53
Change
+$0.12 (+4.98%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
683.65M
21 days until earnings call
Intraday Buy/Sell Signals
LYEL
Price
$16.86
Change
+$0.03 (+0.18%)
Updated
Oct 14 closing price
Capitalization
320.54M
Intraday Buy/Sell Signals
Interact to see
Advertisement

ERAS vs LYEL

Header iconERAS vs LYEL Comparison
Open Charts ERAS vs LYELBanner chart's image
Erasca
Price$2.53
Change+$0.12 (+4.98%)
Volume$100
Capitalization683.65M
Lyell Immunopharma
Price$16.86
Change+$0.03 (+0.18%)
Volume$30.11K
Capitalization320.54M
ERAS vs LYEL Comparison Chart in %
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LYEL commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and LYEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (ERAS: $2.41 vs. LYEL: $16.86)
Brand notoriety: ERAS and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 53% vs. LYEL: 65%
Market capitalization -- ERAS: $683.65M vs. LYEL: $320.54M
ERAS [@Biotechnology] is valued at $683.65M. LYEL’s [@Biotechnology] market capitalization is $320.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLYEL’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LYEL’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while LYEL’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 4 bearish.
  • LYEL’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ERAS and LYEL are a good buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а -2.82% price change this week, while LYEL (@Biotechnology) price change was -4.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($684M) has a higher market cap than LYEL($321M). LYEL YTD gains are higher at: 31.719 vs. ERAS (-3.984). ERAS has higher annual earnings (EBITDA): -135.93M vs. LYEL (-199.95M). ERAS has more cash in the bank: 301M vs. LYEL (277M). LYEL has less debt than ERAS: LYEL (46.6M) vs ERAS (49.4M). LYEL has higher revenues than ERAS: LYEL (60K) vs ERAS (0).
ERASLYELERAS / LYEL
Capitalization684M321M213%
EBITDA-135.93M-199.95M68%
Gain YTD-3.98431.719-13%
P/E RatioN/AN/A-
Revenue060K-
Total Cash301M277M109%
Total Debt49.4M46.6M106%
TECHNICAL ANALYSIS
Technical Analysis
ERASLYEL
RSI
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
88%
Momentum
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 8 days ago
86%
MACD
ODDS (%)
Bullish Trend 8 days ago
72%
Bullish Trend 8 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 8 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
86%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 23 days ago
88%
N/A
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 8 days ago
90%
Aroon
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 8 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NNWWF30.11N/A
N/A
North West Company, Inc. (The)
TRAGF0.73N/A
N/A
Terago Inc.
PSPSY35.14N/A
N/A
PSP Swiss Property
KYCCF385.00-8.13
-2.07%
Keyence Corp.
KLDCF1.42-0.08
-5.33%
Kenorland Minerals Ltd.

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.42%
XNCR - ERAS
56%
Loosely correlated
-10.96%
OCUL - ERAS
53%
Loosely correlated
-5.23%
RVMD - ERAS
50%
Loosely correlated
-2.56%
IRON - ERAS
50%
Loosely correlated
+1.45%
ACLX - ERAS
48%
Loosely correlated
+1.28%
More

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with ERAS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+0.18%
ERAS - LYEL
37%
Loosely correlated
+0.42%
TYRA - LYEL
37%
Loosely correlated
-3.06%
CRBU - LYEL
36%
Loosely correlated
+2.52%
BEAM - LYEL
35%
Loosely correlated
+0.12%
OLMA - LYEL
32%
Poorly correlated
-0.09%
More